Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

• Published in: European journal of haematology 2013-11, Vol.91 (5), p.423-436
• Main Authors: Rodeghiero, Francesco, Stasi, Roberto, Giagounidis, Aristoteles, Viallard, Jean-François, Godeau, Bertrand, Pabinger, Ingrid, Cines, Douglas, Liebman, Howard, Wang, Xuena, Woodard, Paul
• Format: Article
• Language: English
• Subjects: Adult; adverse events; Aged; Biopsy; Child; Clinical Trials as Topic; Humans; immune thrombocytopenia; Intracranial Hemorrhages - etiology; Intracranial Hemorrhages - pathology; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Purpura, Thrombocytopenic, Idiopathic - metabolism; Purpura, Thrombocytopenic, Idiopathic - pathology; Receptors, Fc - administration & dosage; Receptors, Thrombopoietin - agonists; Receptors, Thrombopoietin - metabolism; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Reticulin - metabolism; review; romiplostim; Thrombopoietin - administration & dosage; Thrombopoietin - adverse effects; Thrombosis - etiology; Thrombosis - pathology; Treatment Outcome
• ISSN: 0902-4441; 1600-0609; 1600-0609
• DOI: 10.1111/ejh.12181

Background and objectives Thrombopoietin receptor agonists (TPOra) are the only treatments for immune thrombocytopenia (ITP) for which evidence of efficacy and safety from randomized, placebo‐controlled trials is available. We sought to determine the long‐term tolerability of the TPOra romiplostim, with a particular focus on thrombosis, bleeding, bone marrow (BM) reticulin, neoplasms/haematological malignancies and fatal events. Methods Data from 13 romiplostim clinical trials in which 653 patients with ITP received romiplostim for up to 5 yr (921.5 patient‐years) were pooled; subject incidence rates and exposure‐adjusted event rates (per 100 patient‐years) were calculated. Results The rate of thrombotic events (6% of patients, 7.5 events per 100 patient‐years) did not appear to increase over time; 9 events were associated with platelet counts >400 × 109/L and 10 with romiplostim doses exceeding current recommendations. Serious and grade ≥3 bleeding each occurred in approximately 8% of patients (~11 events per 100 patient‐years). Adverse events of BM reticulin were recorded for 12 patients (1.8%, 1.3 events per 100 patient‐years, confirmed by bone biopsy in ten patients) and BM collagen for one patient (0.2%, 0.1 event per 100 patient‐years, confirmed by trichrome staining). Neoplasms and haematological malignancies occurred in 2.1% and 0.8% of patients, respectively (2.2 and 0.7 events per 100 patient‐years). Fatal events occurred in 3.7% of patients (2.6 events per 100 patient‐years, four events treatment‐related). Conclusions Romiplostim is the TPOra for which the longest duration of safety data is available. Our data demonstrate that long‐term romiplostim treatment is well tolerated, with no new safety signals, even in patients treated for up to 5 yr.